Antibodies reactive with biological markers of benign prostate hyperplasia
US5639656A · kind A · utility
22Cited by
5References
12Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 31, 1994 |
| Grant date | Jun 17, 1997 |
| Priority date | — |
| Expiry date | Mar 31, 2014 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides compositions and methods for use in detecting benign prostate hyperplasia (BPH) and for differentiating BPH from normal prostate tissues and prostate cancer. Disclosed are monoclonal antibodies (MAbs) directed against a highly restricted biological marker of BPH, hybridoma cells secreting such MAbs and various methods for making and using BPH-specific antigens and antibodies, including methods and kits for the detection of BPH antigens and the diagnosis and therapy of BPH.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.